Feature | AmniSure |
Cited in more than 30 publications | ✔ |
~99% correlation to indigo carmine (3) | ✔ |
Detects high concentration of PAMG-1 (4) | ✔ |
No gestational age limitation (4) | ✔ |
No speculum required (4) | ✔ |
Reliability in blood (5) | ✔ |
Rapid, reliable testing
AmniSure is the world’s leading ROM biomarker test and can be implemented quickly and easily within your facility’s existing policies and procedures. Including AmniSure as part of the ROM assessment can provide additional insight to guide clinical decisions.
Accurate insights
Other available ROM immunoassays measure the concentration of alternative biomarkers. However, IFU data of other commercially available ROM biomarker tests reveal that the presence of relevant PAMG-1 is a more accurate measure of ROM status (4,8,9).
See how AmniSure performance compares to other ROM biomarker tests available today.
AmniSure ROM Test (4) |
ROM Plus® test (8) |
Actim® PROM (9) |
|
Amniotic fluid biomaker(s) |
PAMG-1 |
IGFBP-1 (PP12) & AFP |
IGFBP-1 |
Overall specificity |
97.36% |
75.0% |
91.0% without speculum |
Overall sensitivity |
96.64% |
99.1% |
90.1% without speculum |
Ready and reliable
AmniSure is accurate, is ready to use as packaged with no additional tools necessary, can be administered bedside or in the lab by qualified staff, and has no gestational age limitation – enabling a fast and effective response in almost any situation when ROM is suspected.
With up to 30% of suspected ROM patients presenting with vaginal bleeding (5), it is critical to have a ROM test that is easily accessible and performs as intended, even in the presence of blood. In a published study, AmniSure was shown to be the most accurate and readable in the presence of vaginal bleeding (5).
Quick Reference Guide
AmniSure enables a fast and effective response in almost any situation where ROM is suspected. Our Quick Reference Guide details the four simple steps to perform the test and read the results.
Connect with AmniSure Specialist!
Learn more about implementing AmniSure in your facility.
References
- Abdelazim, I.A. and Makhlouf, H.H. (2012) Arch. Gynecol. Obstet. 285, 985-989.
-
Neil, P.R. and Wallace, E.M. (2010) Is Amnisure useful in the management of women with prelabour rupture of the membranes? Aust. N. Z. J. Obstet. Gynaecol. 50, 534–8.
- Sosa C.G., et al. (2014) Comparison of placental alpha microglobulin-1 in vaginal fluid with intra-amniotic injection of indigo carmine for the diagnosis of rupture of membranes. J Perinat Med. 42, 611-16.
- Amnisure IFU https://www.qiagen.com/de/resources/
resourcedetail?id=d91f71db-e3bc-4c16-b654-1831d2fe322c&lang=en - Ramsauer, B., Duwe, W., Shlehe, B., et al. (2015) Effect of blood on ROM diagnosis accuracy of PAMG-1 and IGFBP-1 detecting rapid tests. J. Perinat. Med. 43(4), 417
- Ng, B.K. et al. (2013) Biomed. Res. Int. 587438.
- Cousins, L. M. et al. (2005) Am. J. Perinatol. 22. 317-320.
- ROM Plus IFU https://www.laborie.com/wp-content/uploads/2021/07/OB-MAN-001-EN-ART0087REV02-ROM-Plus-IFU.pdf
- Actim PROM IFU https://www.coopersurgical.com/wp-content/uploads/Actim-PROM-Test-Kit-Instructions-for-Use.pdf